Peripheral urocortin inhibits gastric emptying and food intake in mice: Differential role of CRF receptor 2

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 281, Issue 5 50-5, 2001, Pages

  Wang, L ^a   Martinez V ^a   Rivier, J E ^a   Tache Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antisauvagine 30; Astressin B; Capsaicin; Cholecystokinin; Corticotropin releasing factor; CP 154,526; DMP904

Indexed keywords

ANTISAUVAGINE 30; ASTRESSIN B; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CAPSAICIN; CHOLECYSTOKININ OCTAPEPTIDE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; DMP 904; UNCLASSIFIED DRUG; UROCORTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FOOD INTAKE; HYPOPHAGIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH EMPTYING;

EID: 0035199423     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.2001.281.5.r1401     Document Type: Article

References (57)

1. Characterization of three corticotropin-releasing factor receptors in catfish: A novel third receptor is predominantly expressed in pituitary and urophysis
2. 2 a and β splice variants: Pharmacological characterization using radioligand binding and a luciferase gene expression assay
3. Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice
4. Neuronal pathways involved in abdominal surgery-induced gastric ileus in rats
5. Synergistic interaction between leptin and cholecystokinin to reduced short-term food intake in lean mice
6. Urocortin expression in rat brain: Evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors
7. Peripheral bombesin induces c-fos-like immunoreactivity in the rat brain
8. Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor i deficiency in mice
9. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway
10. Pituitary-adrenal and vagus modulation of sauvagine- and CRF-induced inhibition of gastric emptying in rats
11. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain
12. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2
13. Corticotropin-releasing factor receptors: An overview
14. Cloning and characterization of human urocortin
15. The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo- [1,5-a]-pyrimidine: A corticotropin-releasing factor (hCRF1) antagonist
16. Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents
17. Vagotomy abolishes cues of satiety produced by gastric distension
18. Urocortin mRNA is expressed in the enteric nervous system of the rat
19. 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-l,3,5-triazine: A potent, orally bioavailable CRF(1) receptor antagonist
20. 125I-Antisanvagine-30: A novel and specific high affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors
21. Peripheral administration of CRF and urocortin: Effects on food intake and the HPA axis in the marsupial Sminthopsis crassicaudata
22. Pretreatment with glucose increases entry of urocortin into mouse brain
23. Activation of urocortin transport into brain by leptin
24. Peripheral administration of urocortin suppresses operant responding for food reward
25. CRF 2α and CRF2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues
26. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence
27. Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type i receptor in rats
28. Peripheral injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats
29. Acute modulation of active carrier-mediated brain-to-blood transport of corticotropin-releasing hormone
30. Capsaicin pre-treatment attenuates multiple responses to cholecystokinin in rats
31. Recent advances with the CRF1 receptor: Design of small molecule inhibitors, receptor subtypes and clinical indications
32. Cholecystokinin suppresses food intake by inhibiting gastric emptying
33. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa
34. Effects of sauvagine, urotensin I and CRF on food intake in rats
35. Effects of newly developed CRF receptor antagonist, astressin B, on peripheral CRF-induced gastric relaxation
36. Peripheral urocortin delays gastric emptying: Role of CRF receptor 2
37. Distribution and concentration of urocortin, and effect of adrenalectomy on its content in rat hypothalamus
38. Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF
39. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart
40. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of CRF receptors
41. Corticotropin releasing factor receptors and their ligand family
42. + currents
43. Gastric volume rather than nutrient content inhibits food intake
44. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: Differential roles of CRF receptors 1 and 2
45. Secretin inhibits gastric emptying in rats via a capsaicin-sensitive vagal afferent pathway
46. Cholecystokinin inhibits gastric motility and emptying via a capsaicin-sensitive vagal pathway in rats
47. Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat
48. Receptor-selective corticotropin releasing factor analogs
49. Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat
50. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2β-selective antisauvagine-30
51. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors
52. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors
53. The neurobiology of urocortin
54. 2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia
55. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor
56. Fos expression in the brain induced by peripheral injection of CCK or leptin plus CCK in fasted lean mice
57. Fos induction in selective hypothalamic neuroendocrine and medullary nuclei by intravenous injection of urocortin and corticotropin-releasing factor in rats